The recent Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) trial found that in overweight/obese individuals with CVD and no diabetes, treatment with GLP‐1 RA reduced the risk of a composite outcome of cardiovascular death, nonfatal myocardial infarction (MI), or nonfatal stroke by 20% [11]. The gene discussed is GLP1R; the disease is stroke disorder.